Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Laekna Therapeutics Secures $527M Global Licensing Deal with Vasque Bio for PI3Kα Inhibitor LAE118, Retaining China Rights

Fineline Cube Jun 10, 2026
Company Deals

Everest Medicines Secures Asia-Pacific Rights to Vcare Pharma’s Next-Generation P2Y12 Inhibitor Sumecigrel in $3M Licensing Deal

Fineline Cube Jun 9, 2026
Company Deals Drug

Shandong Buchang Pharmaceuticals Partners with Vietnamese MKT for Exclusive Adalimumab Biosimilar Distribution in Vietnam

Fineline Cube Jun 9, 2026
Company Deals

Konruns Pharmaceutical to Acquire 30% Stake in Huamao Pharma for $28.2 Million, Achieving Vertical Integration from API to Finished Formulation

Fineline Cube Jun 9, 2026
Company Deals

Hangzhou Highlightll Pharmaceutical Files for Hong Kong IPO with Seven-Candidate Pipeline Targeting Autoimmune and Neurodegenerative Diseases

Fineline Cube Jun 9, 2026
Policy / Regulatory

China’s National Health Commission Launches Anti-Corruption Campaign Targeting Pharmaceutical Sales and Healthcare Services Misconduct

Fineline Cube Jun 10, 2026
Company Drug

Lynk Pharmaceuticals and Formation Bio Dose First Patient in Phase I BLKR201 Study for CNS-Penetrant TYK201 Inhibitor, Backed by $605M Partnership

Fineline Cube Jun 10, 2026
Company Drug

Zai Lab Launches Commercial Rollout of Cobenfy in China Following First Nationwide Prescription for Schizophrenia Treatment

Fineline Cube Jun 10, 2026
Company Deals

Roche Partners with Broad Clinical Labs to Advance SBX Sequencing Technology

Fineline Cube May 26, 2025

Swiss giant Roche AG (SWX: ROG, OTCMKTS: RHHBY) announced last week a strategic partnership with...

Company Drug

Grand Pharma’s GPN01768 Approved in Macau for Demodectic Blepharitis

Fineline Cube May 26, 2025

Grand Pharmaceutical Group Co., Ltd. (HKG: 0512) announced that its New Drug Application (NDA) for...

Company Medical Device

Medtronic’s Prevail DCB Gains CE Mark for Expanded Coronary Disease Indications

Fineline Cube May 26, 2025

US-Irish firm Medtronic (NYSE: MDT) announced that its Prevail paclitaxel-coated percutaneous transluminal coronary angioplasty (PTCA)...

Company Deals

Tonghua Dongbao to Sell Stake in Amoytop Biotech for USD 181 Million

Fineline Cube May 24, 2025

Chinese pharmaceutical firm Tonghua Dongbao Pharmaceuticals Co., Ltd (SHA: 600867) has announced plans to divest...

Company Deals

Shandong Boan Biotechnology Partners with HKUST for Biomedicine Innovation

Fineline Cube May 24, 2025

China-based Shandong Boan Biotechnology Co., Ltd (HKG: 6955) has entered into a partnership with the...

Company Deals

PacBio Appoints Haorui Gene as Official Distributor in China

Fineline Cube May 24, 2025

US-based sequencing solutions provider PacBio (NASDAQ: PACB) has appointed China’s Haorui Gene as an official...

Company Drug

Zhongsheng Pharma’s Anruiwei Receives NMPA Approval for Influenza A

Fineline Cube May 23, 2025

China-based Guangdong Zhongsheng Pharmaceutical Co., Ltd (SHE: 002317) announced that it has received marketing approval...

Company Drug

CARsgen’s Satri-Cel Shows Significant Efficacy in Gastric Cancer Study

Fineline Cube May 23, 2025

China-based CARsgen Therapeutics Holdings Limited (HKG: 2171) announced that it has published an abstract of...

Company Deals

Viz.ai Partners with Sanofi and Regeneron to Deploy AI Solution for COPD

Fineline Cube May 23, 2025

US-based Viz.ai this week announced a multi-year partnership with France-based Sanofi (NASDAQ: SNY) and US-based...

Company Drug

GSK’s Nucala Receives FDA Approval for COPD Treatment

Fineline Cube May 23, 2025

UK-based pharmaceutical giant GlaxoSmithKline (GSK, NYSE: GSK) announced that it has received marketing approval from...

Company Drug

Merck’s Welireg Launched in China for Rare Genetic Disorder Treatment

Fineline Cube May 23, 2025

US-based Merck, Sharp & Dohme (MSD; NYSE: MRK) announced the commercial launch of its hypoxia-inducible...

Company Drug

NMPA Approves Bayer/Regeneron’s Eylea HD for Wet AMD Treatment

Fineline Cube May 23, 2025

China’s National Medical Products Administration (NMPA) has approved Bayer (ETR: BAYN) and Regeneron’s (NASDAQ: REGN)...

Company Drug

Ascentage Pharma to Present Data on Lisaftoclax and Alrizomadlin at ASCO 2025

Fineline Cube May 23, 2025

China-based Ascentage Pharma (NASDAQ: AAPG, HKG: 6855) will present the latest data from two ongoing...

Company Deals

Meinian Onehealth Partners with Alibaba DAMO Academy for AI-Driven Disease Screening

Fineline Cube May 23, 2025

China-based Meinian Onehealth Healthcare (Group) Co., Ltd (SHE: 002044) has entered into a partnership with...

Company Deals

Lead Healthcare Raises RMB 100M in Angel Financing to Boost AI-Driven Life Science Instruments

Fineline Cube May 23, 2025

China-based Lead Healthcare Technology (Guangzhou) Co., Ltd reportedly raised close to RMB 100 million (USD...

Company Deals

WinHealth Pharma Expands Long-Term Partnership with Merz Therapeutics

Fineline Cube May 23, 2025

China-based Hong Kong WinHealth Pharma Group this week formally entered into a long-term partnership with...

Company Deals

Servier Acquires BioNova’s BN104 for Acute Leukemia Treatment

Fineline Cube May 23, 2025

French pharmaceutical firm Servier announced a definitive agreement to acquire BN104 from BioNova Pharmaceuticals (Shanghai)...

Company Drug

ImmuneOnco and Instil Bio Announce Clinical Updates for IMM2510 in NSCLC

Fineline Cube May 23, 2025

China-based ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd (HKG: 1541) and its US partner Instil Bio Inc...

Company Drug Policy / Regulatory

UCB’s Keppra Procurement Resumed in Shanghai After Regulatory Halt

Fineline Cube May 23, 2025

Shanghai’s Sunshine Medical Procurement All-in-One (SMPA) has issued a notification resuming the procurement of UCB’s...

Company Deals

RemeGen Plans Hong Kong Share Placement to Fund Telitacicept Expansion

Fineline Cube May 23, 2025

China-based biopharma RemeGen Ltd (HKG: 9995) announced plans to place 10.2% of its issued shares...

Posts pagination

1 … 171 172 173 … 681

Recent updates

  • Burning Rock Reports Q1 2026 Revenue of $16M, Accelerates Strategic Shift to In-Hospital Testing with 49% Revenue Share
  • China’s National Health Commission Launches Anti-Corruption Campaign Targeting Pharmaceutical Sales and Healthcare Services Misconduct
  • Lynk Pharmaceuticals and Formation Bio Dose First Patient in Phase I BLKR201 Study for CNS-Penetrant TYK201 Inhibitor, Backed by $605M Partnership
  • Zai Lab Launches Commercial Rollout of Cobenfy in China Following First Nationwide Prescription for Schizophrenia Treatment
  • Eli Lilly Secures FDA Approval for Every-Eight-Week EBGLYSS Regimen in Atopic Dermatitis, Offering Just Six Annual Injections
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company

Burning Rock Reports Q1 2026 Revenue of $16M, Accelerates Strategic Shift to In-Hospital Testing with 49% Revenue Share

Policy / Regulatory

China’s National Health Commission Launches Anti-Corruption Campaign Targeting Pharmaceutical Sales and Healthcare Services Misconduct

Company Drug

Lynk Pharmaceuticals and Formation Bio Dose First Patient in Phase I BLKR201 Study for CNS-Penetrant TYK201 Inhibitor, Backed by $605M Partnership

Company Drug

Zai Lab Launches Commercial Rollout of Cobenfy in China Following First Nationwide Prescription for Schizophrenia Treatment

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.